Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including sig ...

If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.

Henry Schein (HSIC) stock in focus as KKR (KKR) builds stake and the company posts its preliminary Q4 2024 financials. Read ...

Bearish flow noted in GSK (GSK) Pharma with 1,694 puts trading, or 4x expected. Most active are 2/7 weekly 34 puts and Jan-27 28 puts, with total volume in those strikes near 1,600 contracts. The ...

Alphabet also remains a popular pick among hedge fund managers. According to Insider Monkey data, 202 hedge fund investors ...

Moderna MRNA announced that the U.S. government, through the Biomedical Advanced Research and Development Authority (“BARDA”) ...

Look deep into nature and then you will understand everything better.” The quote from Albert Einstein is generally deployed ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

Marketing: Around the world, brands have learnt that revamping their identities without thinking the exercise through can be met with ridicule and derision — often the hard way. On the other hand, ...

Scorpion’s current shareholders will own the new company, and Lilly will have a minority stake. GSK, meanwhile, announced an agreement to acquire private biotech IDRx, which makes precision ...

Learn More Pharmaceutical giant GSK is pushing the boundaries of what generative AI can achieve in healthcare areas like scientific literature review, genomic analysis and drug discovery.

Walmsley said GSK had a successful partnership with the first Trump administration and she was “optimistic and ambitious” looking into 2025. “Obviously there is a lot of commentary on what the new ...